Mehrdad Abedi

Mehrdad Abedi serves as a Professor of Medicine in the Internal Medicine Department at the University of California, Davis School of Medicine. His clinical practice focuses on malignant hematology and cellular therapy within the UC Davis Comprehensive Cancer Center and Transplant Center.

His research spans hematopoietic stem cells, bone marrow transplantation models, and gene/cellular therapies. Abedi's work demonstrates significant contributions to CAR T-cell therapy for B-cell acute lymphoblastic leukemia, as evidenced by multiple ZUMA-3 trial publications. His laboratory investigations explore novel cellular therapy applications for hematological malignancies and genetic disorders.

Key publication trends show concentrated research in 2021-2025 on CAR T-cell therapies (particularly brexucabtagene autoleucel), with substantial clinical trial involvement in lymphoma, leukemia, and myeloma treatment. His work bridges basic science in stem cell biology with translational applications in refractory hematological malignancies.

Scientific Recognition:

• Alpha Clinic Award, UC Davis Health (2017)

Dr. Abedi maintains active leadership in professional societies including the American Society for Blood and Marrow Transplantation, American Society of Hematology, and Southwest Oncology Group. His clinical philosophy emphasizes team-based care involving nurses, pharmacists, and social workers to deliver comprehensive patient management. While specific grant details aren't provided, his extensive clinical trial participation suggests substantial research funding support.